FBTAX Holdings — Fidelity Advisor Biotechnology Fund
All 98 reported holdings of Fidelity Advisor Biotechnology Fund (FBTAX) by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets | Value (USD) |
|---|---|---|
| Abbvie, Inc. | 14.83% | $282.21M |
| Alnylam Pharmaceuticals, Inc. | 5.52% | $105.07M |
| Gilead Sciences, Inc. | 5.42% | $103.22M |
| Insmed, Inc. | 3.51% | $66.75M |
| Cogent Biosciences, Inc. | 3.45% | $65.67M |
| Dianthus Therapeutics, Inc. | 3.37% | $64.10M |
| Spyre Therapeutics, Inc. | 3.33% | $63.41M |
| Ascendis Pharma A/s | 3.24% | $61.75M |
| Argenx SE | 3.17% | $60.35M |
| Biogen, Inc. | 2.92% | $55.67M |
| Oruka Therapeutics, Inc. | 2.65% | $50.44M |
| Fidelity Revere Street Trust | 2.51% | $47.78M |
| Amgen, Inc. | 2.46% | $46.78M |
| Vaxcyte, Inc. | 2.30% | $43.71M |
| Revolution Medicines, Inc. | 2.27% | $43.16M |
| Nuvalent, Inc. | 2.17% | $41.34M |
| Amylyx Pharmaceuticals, Inc. | 2.05% | $38.93M |
| Apogee Therapeutics, Inc. | 1.97% | $37.52M |
| Moderna, Inc. | 1.55% | $29.44M |
| Xenon Pharmaceuticals, Inc. | 1.34% | $25.58M |
| Viridian Therapeutics, Inc. | 1.26% | $24.03M |
| Kiniksa Pharmaceuticals International PLC | 1.18% | $22.46M |
| Roivant Sciences Ltd. | 1.16% | $22.16M |
| Jade Biosciences, Inc. | 1.15% | $21.82M |
| Praxis Precision Medicines Inc. | 1.14% | $21.65M |
| Crinetics Pharmaceuticals, Inc. | 1.11% | $21.11M |
| Cytokinetics, Inc. | 1.05% | $20.01M |
| Structure Therapeutics, Inc. | 1.05% | $19.95M |
| Kymera Therapeutics, Inc. | 0.99% | $18.78M |
| Natera, Inc. | 0.97% | $18.43M |
| Ucb SA | 0.93% | $17.69M |
| Newamsterdam Pharma Company NV | 0.88% | $16.75M |
| Fidelity Revere Street Trust | 0.77% | $14.68M |
| Viking Therapeutics, Inc. | 0.74% | $14.04M |
| Enliven Therapeutics, Inc. | 0.71% | $13.56M |
| Relay Therapeutics, Inc. | 0.70% | $13.33M |
| Fabio Tub Holdings LLC | 0.67% | $12.77M |
| Tyra Biosciences, Inc. | 0.65% | $12.31M |
| Zenas Biopharma, Inc. | 0.62% | $11.80M |
| Olema Pharmaceuticals, Inc. | 0.59% | $11.20M |
| Celldex Therapeutics, Inc. | 0.59% | $11.18M |
| Travere Therapeutics, Inc. | 0.56% | $10.68M |
| Cg Oncology, Inc. | 0.55% | $10.52M |
| Stoke Therapeutics, Inc. | 0.55% | $10.40M |
| Annexon, Inc. | 0.51% | $9.75M |
| Rhythm Pharmaceuticals, Inc. | 0.50% | $9.55M |
| Cytomx Therapeutics, Inc. | 0.49% | $9.41M |
| Disc Medicine, Inc. | 0.49% | $9.39M |
| Mbx Biosciences, Inc. | 0.48% | $9.21M |
| Mineralys Therapeutics, Inc. | 0.46% | $8.82M |
| Tango Therapeutics, Inc. | 0.46% | $8.73M |
| Dyne Therapeutics, Inc. | 0.44% | $8.46M |
| Alumis, Inc. | 0.43% | $8.16M |
| Damora Therapeutics, Inc. | 0.40% | $7.65M |
| Axsome Therapeutics, Inc. | 0.39% | $7.44M |
| Maplight Therapeutics, Inc. | 0.34% | $6.47M |
| Neurogene, Inc. | 0.33% | $6.36M |
| Upstream Bio, Inc. | 0.33% | $6.34M |
| Taysha Gene Therapies, Inc. | 0.32% | $6.01M |
| Crescent Biopharma, Inc. | 0.30% | $5.62M |
| Definium Therapeutics, Inc. | 0.29% | $5.56M |
| Scholar Rock Holding Corp. | 0.29% | $5.51M |
| X4 Pharmaceuticals, Inc. | 0.29% | $5.46M |
| Solid Biosciences, Inc. | 0.26% | $4.92M |
| Avalo Therapeutics, Inc. | 0.25% | $4.80M |
| Janux Therapeutics, Inc. | 0.24% | $4.60M |
| First Tracks Biotherapeutics, Inc. | 0.24% | $4.49M |
| Edgewise Therapeutics, Inc. | 0.23% | $4.47M |
| Uniqure N.v. | 0.23% | $4.46M |
| Tenax Therapeutics, Inc. | 0.22% | $4.23M |
| Inventiva SA | 0.18% | $3.52M |
| First Tracks Biotherapeutics, Inc. | 0.18% | $3.45M |
| Endeavor Biomedicines, Inc. | 0.18% | $3.43M |
| Tectonic Therapeutic, Inc. | 0.18% | $3.38M |
| Parabilis Medicines, Inc. | 0.17% | $3.31M |
| Kartos Therapeutics, Inc. | 0.17% | $3.19M |
| Sonoma Biotherapeutics, Inc. | 0.17% | $3.17M |
| Enliven Therapeutics, Inc. | 0.16% | $3.02M |
| Mentari Therapeutics, Inc. | 0.12% | $2.33M |
| Lifemine Therapeutics, Inc. | 0.12% | $2.30M |
| Crescent Biopharma, Inc. | 0.12% | $2.20M |
| Bright Peak Therapeutics Inc. | 0.12% | $2.19M |
| Candid Therapeutics | 0.11% | $2.10M |
| Sonoma Biotherapeutics, Inc. | 0.11% | $2.06M |
| Parabilis Medicines, Inc. | 0.10% | $1.96M |
| Rallybio Corp. | 0.10% | $1.88M |
| Cardurion Pharmaceuticals, Inc. | 0.10% | $1.83M |
| Zenas Biopharma, Inc. | 0.09% | $1.67M |
| T-Knife Therapeutics, Inc. | 0.05% | $910.07K |
| Wugen, Inc. | 0.05% | $899.43K |
| Wugen, Inc. | 0.05% | $865.73K |
| Bright Peak Therapeutics Inc. | 0.04% | $777.51K |
| Veradermics, Inc. | 0.04% | $732.60K |
| Treeline Biosciences | 0.02% | $401.74K |
| Cyclerion Therapeutics, Inc. | 0.01% | $216.03K |
| Kartos Therapeutics, Inc. | 0.01% | $169.77K |
| Enliven Therapeutics, Inc. | 0.00% | $7 |
| Afferent Pharma | 0.00% | $19 |
FBTAX overview: performance, fees, allocation and SEC filings